肿瘤细胞免疫治疗的研究进展  

Advances of cell immunotherapy in human cancers

作　　者：张百红 岳红云 ZHANG Baihong;YUE Hongyun(Department of Oncology,the 940 th Hospital of Joint Logistics Support Force of People's Liberation Army,Lanzhou 730050,China)

机构地区：[1]解放军联勤保障部队第九四○医院肿瘤科,兰州730050 [2]解放军联勤保障部队第九四○医院眼科,730050

出　　处：《临床肿瘤学杂志》2021年第6期564-568,共5页Chinese Clinical Oncology

基　　金：甘肃省自然科学基金资助项目(1308RJZA181)。

摘　　要：嵌合抗原受体(CAR)T细胞已成为精准和即用的肿瘤治疗“药物”,基于γδT细胞、自然杀伤(NK)细胞和巨噬细胞的免疫治疗也逐渐应用到实体瘤中。免疫细胞的毒性、抵抗、休眠、衰老、耗竭、脱靶、自食和失功能等因素限制了其治疗效果,提高编辑技术、应用纳米传输、改善免疫微环境和免疫联合治疗等方法可以提高免疫治疗抗肿瘤反应。本文系统综述肿瘤细胞免疫治疗的主要类型、限制因素和改进方法。Chimeric antigen receptor(CAR)T-cells are on the market as precision and off-the-shelf anticancer drugs.γδT cells,natural killer cells or macrophages-based immunotherapy are being investigated intensively in solid tumors.Cancer immunotherapy toxicity,resistance,quiescence,senescence,exhaustion,off-target,cooperative killing,and dysfunction limited durable responses for numerous tumor types.Genome editing,delivery technologies,microenvironment normalization and combination immunotherapy can enhance the efficacy of cell immunotherapy.This review discusses main types,limited factors and improved methods of cell immunotherapy in human cancers.

关 键 词：肿瘤 细胞免疫治疗 过继性免疫治疗 

分 类 号：R730.5[医药卫生—肿瘤]